TO THE EDITOR
In common with other Src family-related members, the tyrosine kinase fyn has been implicated in malignant pathological processes, including melanoma progression, genesis of neuroblastoma, or carcinoma invasion. 1 The expression of fyn in hematological malignancies is, however, not known. Fyn is transcribed in hematopoietic tissues and in the central nervous system (CNS). Two main isoforms, FynB and FynT, arise by alternative splicing of the fyn gene exon 7A and 7B, respectively. FynT is expressed in the hematopoietic lineage and FynB in the brain. 2 In hematopoïetic tissues and in the CNS, alternative splicing of exon 7A or 7B is mutually exclusive. It would be secondary to the capture of exon 7A by the ancestral fyn gene, which was recruited by the brain while the ancestral exon 7B was conserved and expressed in the hematopoietic lineage. 3 The exon 7 sequences encode for the linker region involved in intramolecular interactions controlling Src tyrosine kinase regulation. 1 Ex vivo experiments showed that the two isoforms possess distinct signaling and transforming capabilities. 4, 5 Hence, altered splicing of fyn messengers might contribute to altered Fyn function in specific tissues. Indeed, it was shown that fynB mRNA was strongly upregulated in a HTLV1-infected T cell line (C91). 6 These data suggest that, under certain conditions, the regulation of the alternative splicing can be modulated and that the FynB isoform could be expressed in lymphocytes. However, mRNA and protein expression profiles of both isoforms have not yet been studied in detail in lymphoid cells.
We developed primer sets to specifically PCR amplify fynT and fynB transcripts, as described in Figure 1a . Specific amplification was validated using fynT and fynB plasmid constructs as templates and using known tissues expressing either fynT (thymus and spleen) or fynB (brain) (Figure 1b and c) . Surprisingly, fynT and fynB mRNAs were present at similar levels in other tissues, including heart, liver, lung, kidney and intestine (Figure 1d ). These data confirm the broad expression pattern of fyn and suggest either the existence of specific mechanisms responsible for exclusive splicing of exon 7A and 7B in the brain or in immune cells, or, alternatively, the lack in immune and brain cells of the machinery present in other tissues and that allows for both fynT and fynB co-transcription. This mutually exclusive splicing was then investigated at the cell level. Both fynT and fynB mRNAs were detected at variable levels in transformed cells of either hematopoïetic or nonhematopoïetic origin (Figure 1e ). However, fynT was the almost exclusive fyn transcript in primary cultures of peripheral blood T and B lymphocytes, natural killer cells, monocytes and dendritic cells (Figure 1f ). Although fynB mRNA was clearly amplified in lymphoid T-cell lines, it could not be detected in either quiescent or primary T-cell cultures activated by PMA þ ionomycin or PMA þ IL2 up to 7 days (Figure 1g ). Hence, fynT mRNA is the exclusive transcribed isoform in primary cultures of cells of the immune system. Recently, it was shown that fynB messenger was strongly upregulated in the C91 HTLV1-infected T-cell line. Our RT-PCR analysis confirms and extents these observations to other acute lymphoblastic leukemia (ALL) cell lines infected or not by HTLV1 or EBV. It is thus possible that, under certain pathological conditions, associated or not with HTLV1 infection, fynB mRNA is expressed in lymphoid cells.
These data were next confirmed in fresh cells isolated from ALL and chronic lymphocytic leukemia (CLL) patients, after informed consent. The cDNA of two fyn isoforms were clearly separated on DNA 500 Labchips (Agilent Technology), as shown in Figure 2a . FynB transcript was significantly detected in 11/16 and 19/24 ALL and CLL patients, respectively ( Figure 2b ). The proportional amounts of the two fyn isoforms were determined by the relative ratio of areas of the two peaks in the chromatogram, showing that variation in the relative amount of fynB mRNA is independent of pathologies and accounts on average for 30% of fyn transcripts (ranging from 0 to 60%) in ALL and 19% (ranging from 0 to 60%) in CLL patients (Figure 2b ).
For these pathologies, the absence of serologic tools allowing to distinguish between both Fyn isoforms led us to generate an anti-FynB polyclonal rabbit antibody that allowed for the specific detection by Western blotting of the FynB but not the FynT protein contained either in cell lysates or anti-Fyn immunoprecipates obtained from transfected COS cells (Figure 3a) . FynB was also revealed in Fyn immunoprecipitates obtained from brain, but neither spleen nor thymus tissues (Figure 3b) , consistent with the RT-PCR analysis. Surprisingly, the FynB protein was not detected in Fyn immunoprecipitates obtained from C91 and Jurkat JH6.2 cells (Figure 3b) , despite similar or even higher levels of PCR amplification products of fynB over fynT mRNA in these cells (Figure 1e ). In similar experimental conditions, the FynB protein was clearly present in HeLa-and HEK293-derived Fyn immunoprecipitates. Three CLL samples displaying the greatest relative amount of FynB transcritpt (60, 50 and 36%) were similarly analyzed by Western blotting, showing undetectable FynB in Fyn immunoprecipitates (Figure 3c) .
Thus, in this study, fynB mRNA was not detected in primary cultures of cells of the hematopoietic lineage, excluding a role for this fyn-encoded isoform in hematopoïetic cells. However, certain pathological processes, such as ALL and CLL, yield an inappropriate fynB transcription. In this situation, the FynB protein was not detected, indicating that a translational block prevented detectable FynB accumulation. In hematopoïetic transfected cells, the FynB protein displayed a significantly higher stability than FynT (CP, unpublished results), excluding that absence of FynB in Fyn immunoprecipitates resulted from protein degradation. Competitive translation of fynT and fynB mRNA is also unlikely to be involved, since FynB protein could be detected in HeLa and 293 cells, both transcribing the two isoform messengers. However, we cannot exclude slight levels of FynB translation, undetectable by our immunoprecipitation and Western blotting analysis. So, this study shows that, in CLL or ALL, oncogenic and viral factors such as Rex in HTLV1-infected cells could modulate fyn alternative splicing but not its translation, suggesting that the stability or localization of the mature fynB mRNA could be altered.
The mechanisms involved in the alternative splicing and translational control of fyn are not known. mRNA degradation is a tightly regulated process depending on cis-acting sequences and trans-acting factors. Alternative mRNA splicing can modify the regulation of mRNA stability or translation by means of transcripts with similar open reading frames (ORFs), yet divergent 5 0 -or 3 0 -untranslated regions. 7 However, the fyn alternative splicing implicates exon 7A or 7B sequences, not the 5 0 -or 3 0 -untranslated regions. Two species of mRNAs for fyn are produced by an alternative polyadenylation. 8 It thus remains to determine whether alternative splicing of exon 7A or 7B is linked to alternative polyadenylation signals allowing for a distinct tissue-dependent translational regulation.
What could be the biological impact of the present findings? Previous studies have suggested that FynB overexpression could compete with FynT expression and repress its ability to signal. [4] [5] [6] Our results show that such a competitive function of fynB would not stand at the protein level since the FynB protein could not be detected in hematopoietic cells displaying elevated fynB transcripts. However, it remains possible that the alternative splicing of fyn messenger influences the level of the FynT isoform by as yet unknown mechanisms. In CLL, this mechanism could take part in the extensive impairment of signaling pathways such as downstream of the B-cell receptor. Of potential clinical interest, expression of fyn predicts long-term survival in neuroblastoma, and signaling through Fyn has been proposed as a therapeutic avenue for advanced-stage neuro- . Total RNA was isolated using Trizol reagent, as recommended by the manufacturer (Life Technologies, Cergy Pontoise, France). RNA was reverse transcribed, followed by PCR amplification as described previously.
3 M, molecular marker. RT-PCR analysis of heart, liver, lung, kidney and intestine total RNA (Clontech, Palo Alto, CA, USA) (d), cell lines (e) and primary cell cultures (f, g), as in (c). PBMC of healthy donors were isolated on Ficoll-Hypaque gradients. T lymphocytes were isolated as the CD2-positive PBMC population. B lymphocytes and monocytes were obtained from PBMC by positive selection using CD19 and CD14 microbeads, respectively, as recommended by the manufacturer (Miltenyi Biotech, Paris, France). For NK cells, CD3-CD4-DR-cells were obtained by immunomagnetic depletion of PBMC, followed by incubation of cells on irradiated feeder cells in the presence of 100 U/ml of recombinant IL-2 (Proleukin, Chiron, Emerville, CA, USA) and 1.5 ng/ml PHA (Gibco, Paisley, Scotland) to obtain activated NK cell population. For generation of immature DC, PBMC were depleted of nonadherent cells by 4 h adhesion on plastic dishes. Adherent cells were cultured for 5 days in RPMI supplemented with 10% FBS, 100 ng/ml GM-CSF (Novartis, Switzerland) and 10 ng/ml IL-4 (Genzyme, Cambridge, MA, USA) for 6 days. On day 6, final maturation was induced by the addition of 50 ng/ml of TNFa (Promocell, Heidelberg, Germany). In (g), T lymphocytes were stimulated with 1 ng/ml PMA and 1 mg/ml ionomycin (Sigma) for the indicated time. JH6.2 is a Jurkat subclone. blastoma. 9 Which of FynT or FynB is involved was not established in this study. Deciphering the tissue-specific transcriptional and translational mechanisms balancing FynT and FynB expression might thus provide valuable means to differentially control Fyn signaling in distinct pathological settings. Future studies will aim to identify the mechanisms involved in the distinct control of fyn expression, and also to further evaluate the role of fynB mRNA in ALL and CLL, as well as its putative use as a biomarker in these pathologies. 
